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Abstract
Background:  Transcription of large numbers of non-coding RNAs originating from intronic
regions of human genes has been recently reported, but mechanisms governing their biosynthesis
and biological functions are largely unknown. In this work, we evaluated the existence of a common
mechanism of transcription regulation shared by protein-coding mRNAs and intronic RNAs by
measuring the effect of androgen on the transcriptional profile of a prostate cancer cell line.
Results: Using a custom-built cDNA microarray enriched in intronic transcribed sequences, we
found 39 intronic non-coding RNAs for which levels were significantly regulated by androgen
exposure. Orientation-specific reverse transcription-PCR indicated that 10 of the 13 were
transcribed in the antisense direction. These transcripts are long (0.5–5 kb), unspliced and
apparently do not code for proteins. Interestingly, we found that the relative levels of androgen-
regulated intronic transcripts could be correlated with the levels of the corresponding protein-
coding gene (asGAS6 and asDNAJC3) or with the alternative usage of exons (asKDELR2 and asITGA6)
in the corresponding protein-coding transcripts. Binding of the androgen receptor to a putative
regulatory region upstream from asMYO5A, an androgen-regulated antisense intronic transcript,
was confirmed by chromatin immunoprecipitation.
Conclusion: Altogether, these results indicate that at least a fraction of naturally transcribed
intronic non-coding RNAs may be regulated by common physiological signals such as hormones,
and further corroborate the notion that the intronic complement of the transcriptome play
functional roles in the human gene-expression program.
Background
Non-coding RNAs (ncRNAs), particularly those tran-
scribed from genomic regions spanning introns of spliced
genes, have been proposed as a fundamental advance in
the genetic operating system of higher organisms by influ-
encing the genomic program of differentiation and devel-
opment in individuals and species [1,2]. Many functions,
such as transcriptional or translational regulation, RNA
splicing, gene silencing, imprinting and dosage compen-
sation, have been assigned to mammalian ncRNAs [3].
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Most functionally characterized ncRNAs belong to classes
of small RNAs such as microRNAs [4] and small nucleolar
RNAs (snoRNAs) [5]. While several novel long ncRNAs
have been described in mammalian organisms [6,7] few
have been characterized in more detail, the ~15 kb Xist
RNA involved in inactivation of chromosome X being an
exception [8].
Recent studies based on computational analysis and
experimental validation have revealed that both introns
and intergenic regions constitute major sources of
ncRNAs [3,9,10]. Extensive analyses of the human
expressed sequence tags (EST) database have focused par-
ticularly on spliced mRNAs, and ESTs that overlap at least
one exon have identified an abundant number of sense-
antisense transcript pairs in humans [7,11,12], mice [13]
and plants [14], pointing to a well-conserved mechanism
of post-transcriptional regulation of gene expression in
eukaryotes.
Recently, microRNAs have been shown to be consistently
altered in normal and tumor cells, allowing the identifica-
tion of tissue-specific expression signatures [15]. Using a
custom-built cDNA microarray enriched in ESTs corre-
sponding to fragments of intronic transcripts, we previ-
ously detected transcription of a set of totally intronic
ncRNAs, which are long (0.6–1.1 Kb), unspliced, and ori-
ented in the antisense direction relative to the correspond-
ing protein-coding transcript [16]. Moreover, expression
levels of 23 intronic ncRNAs were shown to correlate with
the degree of tumor differentiation in prostate cancer [16].
The potential role of long ncRNAs in human cancer is also
exemplified by MALAT-1, a 7-kb RNA that was reported to
be associated with metastatic non-small cell lung cancer
[17]. Other reports have shown that totally or partially
intronic long antisense transcripts may have regulatory
functions, such as modulating the methylation status of
promoters [18] or the alternative splicing pattern of the
corresponding protein-coding gene [19]. However, little
attention has been given to the mechanism used by the
cell to control the expression of these long intronic RNAs.
Androgens have been implicated in central events govern-
ing the regulation of distinct and diverse physiological
processes in normal and neoplastic prostate cells. These
hormones are known to promote cell division and prolif-
eration of epithelial cells, to modulate programmed cell
death and cell quiescence [20,21] and to regulate cellular
metabolism [22]. More recently, several studies have char-
acterized the temporal transcriptional program reflecting
the cellular response to androgens, which led to the iden-
tification of novel androgen-regulated protein-coding
genes [23-25].
In the present study, to identify androgen-responsive non-
coding intronic RNAs, we used a custom-built spotted
cDNA microarray enriched in intronic transcribed
sequences and a prostate cancer cell line (LNCaP) cul-
tured in the presence of a synthetic androgen. Using ori-
entation-specific reverse transcription followed by PCR
(RT-PCR) we determined the sense or antisense direction
of a subset of intronic transcripts. We found that the levels
of these intronic RNAs in androgen-treated and control
cells correlate with the levels of message or to the alterna-
tive usage of exons in the corresponding protein-coding
transcript. Additional approaches such as rapid amplifica-
tion of the cDNA ends (RACE) and chromatin immuno-
precipitation assays (ChIP) demonstrated that these
intronic messages represent long and unspliced RNA tran-
scripts that may be directly regulated by the androgen
receptor (AR) in vivo. These findings indicate that tran-
scription of long intronic ncRNAs may be controlled by
mechanisms common to protein-coding transcripts, such
as those involving hormonal control of gene-promoter
activation. In addition, our results indicate that a fraction
of this class of long unspliced intronic RNAs may have a
role in post-transcriptional regulation of gene expression
by modulating transcript stability and alternative splicing.
Results and discussion
Identification of intronic RNAs regulated by androgen
We used a spotted cDNA microarray platform enriched in
intronic transcripts [16] to identify intronic RNAs and
exonic protein-coding messages that had significant
changes in transcription levels when hormone-responsive
LNCaP prostate cancer cells were treated with the syn-
thetic androgen R1881. Expression levels of KLK3 (PSA,
prostate-specific antigen) [24] and TMEPAI  [26], two
genes previously shown to be upregulated by androgens
in prostate epithelium, were determined by real-time
PCR, confirming the effectiveness of androgens to induce
responsive genes in our experimental conditions (see
Additional file 1). Next, we used significance analysis of
microarrays (SAM) [27] to identify transcripts that
showed statistically significant changes in levels after
exposure to androgen for periods of 6–48 hours. Only
transcripts showing significant expression changes (≥ 1.5-
fold change and false discovery rate < 5%) for at least three
consecutive time points were selected for further analysis.
We found 168 protein-coding exonic messages (see Addi-
tional file 2) and 39 intronic RNAs (Figure 1A) that had
statistically different patterns of temporal expression in
androgen-treated cells compared with untreated controls
(the complete list of androgen-regulated exonic tran-
scripts coding for proteins is shown in Additional file 3).
Androgen-regulated intronic RNAs could be grouped into
three clusters based on their different temporal patterns of
expression after androgen exposure (Figure 1B). Cluster IBMC Biology 2007, 5:4 http://www.biomedcentral.com/1741-7007/5/4
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Androgen-responsive intronic RNAs Figure 1
Androgen-responsive intronic RNAs. (A) Hierarchical clustering of 39 intronic transcripts significantly upregulated or 
downregulated after androgen exposure. (B) Clusters of intronic transcripts (I-III) with similar temporal expression patterns 
are indicated. Average fold change within each cluster in panel B is indicated by a colored line. (C) Microarray expression pat-
tern of 13 selected androgen-regulated intronic messages selected for orientation-specific reverse-transcription PCR (OSRT-
PCR). (D) Transcriptional orientation of 13 selected androgen-regulated intronic messages relative to the correspondent pro-
tein-coding mRNA determined by OSRT-PCR. Antisense (GAS6, RAB25, ITGA6 and ADD3), sense (ACTN4, STARD3 and ERG) or 
simultaneous antisense and sense (DNAJC3, SAP18, KDELR2, FLJ10154, MYO5A and ATF2) transcription (right panel; antisense, 
sense +RT, + primer) was observed. Controls to monitor the absence of contamination with genomic DNA (right panel; con-
trol - RT, + primer) or the absence of RNA self-priming (right panel; control + RT, - primer) are indicated. Names between 
panels C and D refer to protein-coding RefSeq mRNAs that map to the same loci and define intronic regions where active 
transcription was detected.BMC Biology 2007, 5:4 http://www.biomedcentral.com/1741-7007/5/4
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contained RNAs whose levels were 2–3-fold downregu-
lated within 24 h after androgen exposure and were
restored at 48 h. Clusters II and III included intronic RNAs
that were upregulated by androgen within 24 h and later
restored. Cluster II grouped RNAs that were 2-t3-fold
increased, and cluster III grouped RNAs that were upregu-
lated 3–6-fold. All of these intronic RNAs are unspliced
messages, and apparently have no coding potential as
determined by ESTScan analysis [28] (a complete list of
androgen-regulated intronic RNAs is provided in Addi-
tional file 4).
Most mammalian snoRNAs [5] and a large fraction of
microRNAs [29] are derived from intronic sequences of
protein-coding and noncoding genes. To investigate the
possibility that some of the androgen-regulated intronic
transcripts might be primary transcripts that, after process-
ing, could generate known small RNAs of those classes, we
compared the sequence of the 39 androgen-regulated
intronic RNAs with those of 346 snoRNAs [30] and 383
microRNAs [31]; no similarity was found.
We then investigated the enrichment of specific gene
ontology (GO) categories for androgen-regulated exonic
and intronic transcripts using BiNGO, a gene ontology
comparison tool [32]. We postulated that intronic tran-
scripts represent a new class of RNAs that might act as cis-
regulatory factors [33]. Thus, for each androgen-regulated
intronic transcript we used the GO annotation assigned to
the corresponding protein-coding mRNA mapping to the
same genomic locus. We found no significant enrichment
of specific GO categories (p < 0.05) among the selected
sets of exonic or intronic androgen-regulated transcripts
when a correction for multiple testing was applied. How-
ever, we noted that 13 of the set of 39 androgen-regulated
intronic transcripts belonged to the signal-transduction
GO category (GO no. 0007165). Indeed, some of these
loci have already been implicated in cellular events related
to prostate cell growth and differentiation. For example,
the protein encoded by GAS6 mRNA is a ligand of the Axl
receptor tyrosine kinase, and the Gas6/Axl complex has
been shown to exhibit mitogenic activity in human pros-
tatic cancer cell lines by modulating the PI3K/AKT and
MEK signal-transduction pathways [34]. Similarly, the
transcription factor encoded by ERG, a member of the ETS
family of central genes involved in integrating signals that
regulate cell growth and differentiation, stress responses
and tumorigenesis, has been previously identified as the
most frequently overexpressed proto-oncogene in malig-
nant prostate epithelial cells [35].
Characterization of androgen-regulated intronic RNAs
Orientation-specific RT-PCR was performed (see Methods
for details) on a selected set of androgen-regulated
intronic RNAs (Figure 1C). Sense or antisense orientation
of the intronic RNA relative to the corresponding protein-
coding gene could be unambiguously assigned in most
cases (13 of 17). For most of these (10 of 13) an intronic
antisense RNA could be detected (Figure 1D). For six of
these antisense RNAs (DNAJC3,  SAP18,  KDELR2,
FLJ10154, MYO5A and ATF2) we detected an overlapping
intronic sense message transcribed in the opposite strand.
Four RNAs (GAS6, RAB25, ITGA6 and ADD3) were only
detected in the antisense orientation, and three intronic
messages (ACTN4,  STARD13  and  ERG) were only
detected in the sense orientation (Figure 1D). The intronic
sense transcripts of ACTN4, STARD13 and ERG did not
show coding potential as determined by ESTScan. With-
out further experimentation, we could not determine if
these intronic sense transcripts are novel non-coding
exons present in alternative splicing forms, or if they rep-
resent ncRNAs originated from independent intronic tran-
scriptional units located in the sense strand. However, the
latter explanation concurs with sense intronic transcrip-
tional units that have been observed elsewhere [9,36].
Next, RACE-PCR experiments with cDNA from prostate
adenocarcinoma cells were performed for a selected set of
intronic RNAs to obtain their full-length sequences. This
selected set comprised intronic RNAs transcribed in the
antisense (GAS6  and ITGA6), sense (STARD3) or both
antisense and sense orientations (MYO5A and DNAJC3)
as determined by orientation-specific RT-PCR. RACE
experiments revealed that antisense intronic RNAs from
DNAJC3,MYO5A  and  ITGA6  were long (0.5–0.8 kb),
unspliced transcripts that mapped totally inside the
intronic regions of the corresponding protein-coding gene
(Figure 2A–C). An unspliced, totally intronic sense tran-
script from STARD3 of approximately 1.4 kb was obtained
(Figure 2D). Further analysis of the coding-potential by
ESTScan indicated that extended intronic STARD3 could
generate a 74-residue peptide, but subsequent BLASTp
searches [37] did not show any similarity of this small pre-
dicted product to known proteins in GenBank or to con-
served protein domains at CDD [38]. We found in
GenBank a 3.2-kb mRNA cloned from a brain cDNA
library [GenBank: AK123478] that confirmed and
extended the intronic antisense RNA mapping to the
GAS6 locus. Next, we performed PCR with primers com-
plementary to the cDNA probe mapping to an intron of
GAS6 deposited in the microarray and to the AK123478
mRNA. We obtained a 4.2-kb amplicon, demonstrating
that the GAS6 antisense intronic RNA transcribed in pros-
tate cells was even longer (at least 4.2 kb) than the previ-
ously known RNA (Figure 2E, yellow bar).In silico analysis
using ESTScan [28] failed to identify open reading frames
for extended intronic sequences transcribed from
DNAJC3, ITGA6, MYO5A and GAS6 loci.BMC Biology 2007, 5:4 http://www.biomedcentral.com/1741-7007/5/4
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A strand-specific northern blot confirmed the expression
of a long (~5 kb) GAS6 antisense transcript in various
human tissues (Figure 2F). The observation that andro-
gen-regulated intronic RNAs could be detected in tissues
that are not particularly responsive to this hormone (Fig-
ure 2, panel F) suggests that regulation of the steady-state
levels of these transcripts may also proceed through an
androgen-independent pathway.
Effect of androgen in the levels of intronic RNAs and 
corresponding protein-coding transcripts
Of the androgen-regulated transcripts identified in our
analysis, only KDELR2  and  ADD3  showed detectable
changes in expression levels of both intronic and exonic
transcripts. The intronic ADD3 transcript increased 4.9-
fold (log2 ratio = 2.3) in androgen-treated cells, whereas
the corresponding protein-coding transcript decreased
3.3-fold (log2  ratio = -1.7) in the same experiment.
Intronic KDELR2 transcript levels increased 2-fold (log2
ratio = 1), and the corresponding exonic transcript
increased 2.3-fold (log2 ratio = 1.2) in cells exposed to
androgen relative to control cells (see Additional files 3
and 4). These results indicate that for a given intronic-
exonic pair transcribed in the same locus, the intronic
message may be directly or inversely modulated with
respect to the exonic message after androgen treatment.
Orientation-specific reverse transcription, followed by
quantitative real-time PCR using RNA from treated and
control untreated cells, was used to confirm the change in
levels of intronic transcripts after androgen exposure. We
tested two intronic RNAs that were detected only in the
antisense orientation (GAS6  and  ITGA6), and two
intronic messages in which both antisense and sense tran-
scription were measured (DNAJC3 and KDELR2) (Figure
3A–D, "intronic" panels). In each case, we quantified in
Characterization of androgen-responsive non-coding intronic RNAs Figure 2
Characterization of androgen-responsive non-coding intronic RNAs. Selected intronic transcripts extended by 
RACE-PCR (A-D, red boxes) or gene-specific PCR (E, yellow box) are shown. Extended unspliced antisense intronic transcript 
fragments were mapped to the genomic sequence (A-E, gray lines) relative to the respective spliced protein-coding transcript 
expressed in the opposite strand (A-E, green arrows). Double-stranded cDNA clones spotted on the microarrays are repre-
sented as blue boxes (A-E). A previously described antisense unspliced intronic transcript mapping to GAS6 locus is shown (E, 
black arrow). Chromosome coordinates and the length of extended intronic transcript fragments are indicated. (F) Strand-spe-
cific multi-tissue northern blot using probes complementary to the antisense intronic transcript mapped in the GAS6 locus.BMC Biology 2007, 5:4 http://www.biomedcentral.com/1741-7007/5/4
Page 6 of 14
(page number not for citation purposes)
Antisense intronic transcription may regulate the levels and the post-transcriptional processing of sense protein-coding  mRNAs Figure 3
Antisense intronic transcription may regulate the levels and the post-transcriptional processing of sense pro-
tein-coding mRNAs. (A-D) Expression levels of sense, antisense intronic transcripts ("intronic" panels) or specific exons of 
protein-coding messages ("exonic" panels) from GAS6 (A), DNAJC3 (B), KDELR2 (C) or ITGA6 (D) loci were measured in andro-
gen-treated (black bars) or control cells (white bars). Full-length curator-confirmed mRNAs mapping to each loci are shown as 
black arrows; non-curator-confirmed mRNAs and ESTs are shown by gray arrows; androgen-regulated intronic unspliced tran-
scripts are shown by hashed arrows. Relative fold change (Y axis) indicates the increase or decrease in transcript levels after 
androgen-treatment relative to their levels in untreated control cells. Error bars refer to standard deviations relative to mean 
fold-change values.BMC Biology 2007, 5:4 http://www.biomedcentral.com/1741-7007/5/4
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parallel the expression levels of exons of the correspond-
ing protein-coding gene (Figure 3A–D, "exonic" panels).
We confirmed by quantitative PCR a 10-fold decrease of
the intronic antisense transcript to GAS6 after androgen
stimulation (Fig 3A, intronic panel). Interestingly, pro-
tein-coding messages for GAS6 that contain exons 4 and 5
were upregulated (1.8-fold) under identical experimental
conditions (Figure 3A, exonic panel). We observed that
the levels of sense and antisense intronic RNAs at the
DNAJC3  locus were modulated in opposite directions
after androgen treatment (Figure 3B, intronic panel). The
upregulation observed for the sense intronic RNA from
DNAJC3 after androgen exposure was in agreement with
the results from the microarray experiments (Figure 3B,
intronic panel), and was also observed for the protein-
coding  DNAJC3  transcript (Figure 3B, exonic panel).
Modification in the relative levels of intronic RNAs from
KDELR2 and ITGA6 after androgen treatment was con-
firmed (Figure 3C and 3D, intronic panels). For KDELR2,
both antisense and sense intronic RNA levels were upreg-
ulated by androgen (2.5-fold and 2.0-fold increase,
respectively; Figure 3C, intronic panel). Likewise, the anti-
sense intronic RNA at the ITGA6  locus was 4.2-fold
increased in the presence of androgen (Figure 3D, intronic
panel). However, in these cases we could not detect nota-
ble changes in the relative levels of the respective protein-
coding transcripts when primers designed to measure con-
stitutive exons were used (Figure 3C and 3D, exonic pan-
els).
To accumulate further evidence of functional involvement
of antisense intronic non-coding transcripts on the splic-
ing mechanism [19,33], we investigated the existence of
correlation between their relative levels and the levels of
the corresponding protein-coding mRNAs, using primers
designed to probe regulated exons, that is, exons that are
absent in at least one documented transcript isoform. At
the KDELR2 locus, we found that exons 2 and 3 were
upregulated (2-fold) after androgen treatment (Figure 3C,
exonic panel). Notably, exon 2 was absent in one KDELR2
transcript isoform [GenBank: BP269541]. Therefore, it is
conceivable that the observed increase in the level of
intronic antisense RNA for KDELR2 after androgen treat-
ment may induce increased retention of exon 2. We could
not detect any notable androgen-driven change in the lev-
els of transcripts containing exons 1 and 3 or exons 1 and
4 (Figure 3C, exonic panel). Notwithstanding, we
observed that exon 1 for KDELR2 was downregulated 2.4-
fold after androgen treatment when a pair of primers
designed to probe only this exon was used (Figure 3C,
exonic panel). This result can only be accounted for by the
accumulation after androgen treatment of an as yet
uncharacterized alternative KDELR2  transcript with a
shorter 3' end.
At the ITGA6 locus we found that the levels of a protein-
coding transcript isoform containing a longer terminal
exon (exon 22D) were downregulated 4.2-fold after
androgen treatment (Figure 3D, exonic panel), and thus
inversely correlated with the 4.2-fold increase observed in
the antisense intronic RNA under the same conditions
(Figure 3D, intronic panel). However, it was not possible
to determine whether this result was actually due to
downregulation of the ITGA6 mRNA isoform containing
exon 22D, as we also detected downregulation of another
intronic transcript naturally transcribed in the ITGA6
locus [GenBank: BX537483] that spans the 3' terminal
exon of the gene (Figure 3D).
Non-coding RNAs have been shown to affect splicing of
protein-coding genes [19,39]. HBII-52, a snoRNA was
found to regulate alternative splicing of the serotonin
receptor gene 5-HT2CRA in trans, by binding to a silencing
element in exon Vb of 5-HT2CRA [39]. Lack of HBII-52
expression causes defective 5-HT2CRA  pre-mRNA
processing and probably accounts for the behavioral
problems observed in patients with congenital Prader-
Willi syndrome [39]. A previous study on the FAS locus
has identified a partially intronic antisense RNA that is
naturally transcribed from the first intron of the gene,
which was named Saf [19]. In vitro overexpression of Saf
induced skipping of several 3' exons of Fas mRNA, result-
ing in a Fas protein that was no longer able to anchor to
the cell membrane or to induce Fas-mediated apoptosis
[19]. Our results identify novel intronic antisense RNAs
that might be involved in regulatory mechanisms of alter-
native splicing of protein-coding genes, in analogy to
those observed for HBII-52 and Fas/Saf.
Increased binding of the androgen receptor to an androgen 
response element motif upstream of asMYO5A
Androgen-mediated transcriptional regulation involves
direct hormone interaction with the AR protein and the
translocation of this complex to the nucleus, promoting
specific interactions with DNA (i.e. androgen response
element; ARE) motifs located near or within the target
sequences [40]. To support a mechanism of direct tran-
scriptional control of androgen-regulated intronic RNAs,
we used a bioinformatics approach [24] to look for puta-
tive ARE motifs located upstream of the identified andro-
gen-regulated intronic RNAs. At least one putative ARE
motif was identified for 24 androgen-regulated intronic
transcripts (a complete list of identified putative ARE
motifs is presented in Additional file 5).
ChIP assays were performed to verify functional binding
of AR to a putative regulatory ARE motif located upstream
of the intronic antisense RNA mapping to the MYO5
locus. The assays revealed that after androgen treatment
there was a 2–3-fold increase in asMYO5A  ARE motifsBMC Biology 2007, 5:4 http://www.biomedcentral.com/1741-7007/5/4
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bound to ARs (Figure 4B and 4C, asMYO5A ARE). The
asMYO5A ARE motif is located at a 5' genomic region 812
bp upstream of the region where the antisense MYO5A
intronic transcript maps. Binding of AR to a previously
described functional ARE that regulates transcription of
the PSA gene was tested in parallel as a positive control for
the ChIP assay (Figure 4B, PSA ARE). A genomic region
upstream from TUBA6, a gene that does not contain puta-
tive ARE motifs in its promoter region, was used as a neg-
ative control for non-specific immunoprecipitation of
DNA fragments (Figure 4B, TUBA6).
The presence of a weak band for asMYO5A ARE in control
cell lysates immunoprecipitated with anti-AR (Figure 4B,
asMYO5A  ARE), indicating that binding of AR to
asMYO5A  ARE may occur to some extent in untreated
cells. This may be explained by the presence of trace
amounts of androgen remaining in charcoal-stripped fetal
calf serum added to the cell-culture medium. An alterna-
tive explanation for the background signal of asMYO5A
ARE measured in control cells may be the existence of
small amounts of AR constitutively bound to the chroma-
tin, as described for another transcription factor, cyclic
AMP-responsive element-binding protein (CREB) [41].
The increased binding of AR to the asMYO5A ARE motif is
in agreement with the androgen-induced increased
expression of the antisense intronic MYO5A  RNA
(asMYO5A) detected by microarray (Figure 1), and con-
firmed by orientation-specific reverse transcription fol-
lowed by real-time PCR (Figure 4A). MYO5A encodes an
actin-based processive motor involved in intracellular
trafficking and exocytosis [42]. Tissue-specific Myo5a iso-
forms are originated from alternative exon usage of the
primary transcript, which in turn is thought to modulate
the protein specificity for different cargoes within the cell
[43]. It is conceivable that the increase in asMYO5A levels
in prostate cells in response to androgen affects the rela-
tive levels of the alternatively spliced forms of MYO5A,
thus modulating protein activity or specificity. Together,
these results suggest that functional binding of androgen-
AR activated complexes to regulatory ARE regions is
required to modulate the levels of intronic antisense RNAs
after androgen treatment of prostate cells.
Increased levels of antisense intronic MYO5A transcript correlates to binding of androgen receptor to a putative upstream  androgen response element Figure 4
Increased levels of antisense intronic MYO5A transcript correlates to binding of androgen receptor to a puta-
tive upstream androgen response element. (A) Expression level of antisense intronic transcript of MYO5A was measured 
in androgen-treated (black bars) or untreated control (white bars) cells. Relative fold change (Y axis) shows the increase or 
decrease in transcript levels after androgen treatment relative to their levels in untreated control cells. Error bars refer to 
standard deviations relative to mean fold-change values. Differential expression of antisense MYO5A transcripts was statistically 
significant (p < 0.05) as indicated by asterisks. (B) Cellular lysates from androgen-treated (+) or control cells (-) were used in 
chromatin immunoprecipitation (ChIP) assays in the presence of an antibody reactive with the androgen receptor protein 
(anti-AR). PCR reactions were used for detection of immunoprecipitated DNA containing an androgen response element 
(ARE) located upstream to the MYO5A antisense intronic transcript (asMYO5A ARE) in androgen-treated (+) or untreated con-
trol cells (-). Prostate-specific antigen ARE (PSA ARE), or a non-related genomic sequence upstream of the tubulin α6 gene 
(TUBA6) were used as positive and negative PCR controls, respectively. An unrelated antibody (mouse IgG) was used as a con-
trol for nonspecific immunoprecipitation. Equal volumes of lysates from androgen-treated or control cells (1:100 of total 
lysate) were treated in parallel, and used as loading controls of input DNA for each ChIP assay (input). (C) Enrichment ratios 
of asMYO5A ARE bound to AR in androgen-treated cells relative to control cells. Enrichment ratios (Raw) represent mean 
ratio values calculated from the integrated band intensities obtained at two different PCR cycle numbers (25 and 30 cycles), in 
reactions similar to those of Figure 4B, as described in Methods. Band intensities from input DNA were used to obtain normal-
ized enrichment ratios (normalized). Error bars show the standard deviation of mean ratios.BMC Biology 2007, 5:4 http://www.biomedcentral.com/1741-7007/5/4
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Conclusion
Although there is still no conclusive evidence about the
molecular mechanisms involved in response to androgen,
we postulate that intronic transcripts exert their regulatory
functions by acting in cis through Watson-Crick base-pair-
ing to complementary sense pre-mRNA [33]. The results
presented here corroborate the notion that at least a frac-
tion of these intronic transcripts may directly affect the
levels and/or splicing of the protein-coding transcript
originating in the opposite strand, and concur with previ-
ous reports in the literature [44,45].
It is not yet clear if the intronic transcripts identified in
this work exert their potential regulatory functions as long
(0.5–5 kb) RNAs, or alternatively, as shorter RNAs result-
ing from processing of the primary transcript. Processing
of these androgen-regulated ncRNAs into shorter RNAs of
defined sizes would also raise the possibility that some
may modulate transcriptional or post-transcriptional
events in messages from different loci, in a manner similar
to microRNAs [4]. The identification of possible short
RNAs modulated by androgen will require further work,
such as 15% denaturing polyacrylamide gel electrophore-
sis or northern blots of prostate cells exposed to androgen
in time-course experiments to document the accumula-
tion of the long intronic RNAs, the time course of their
conversion to short RNAs, and the accumulation of possi-
ble short RNA intermediates.
Previous reports have shown that a large number of tran-
scription-factor binding sites (TFBSs) for well-character-
ized transcription factors such as Sp1, c-Myc, p53 and
Creb lie upstream to transcriptionally active intronic
regions [41,46], some of which generate transcripts that
are oriented antisense relative to the known gene [46].
Notably, Cawley et al [46] found that comparable frac-
tions of protein-coding genes and ncRNAs having an
experimentally determined upstream TFBS region were
regulated after exposure to retinoic acid. The results pre-
sented here provide further evidence that ncRNAs tran-
scribed from intronic segments of the human genome
may be regulated by physiological signals that commonly
act on protein coding-transcripts such as hormones. Sim-
ilar results were observed in mice when the effect of
lipopolysaccharide stimulation on the levels of several
long ncRNAs was measured [47]. Together, these results
strongly suggest that at least in mammalian cells intronic
ncRNAs are transcribed in a regulated fashion and there-
fore must exert physiological roles, which corroborates
the existence of a yet underappreciated complex RNA-
based regulatory system involving non-coding messages
in higher organisms [2,3,48].
Methods
Cell culture and RNA isolation
The experimental design was based on recent published
work [24]. In summary, prostate carcinoma cell lines
LNCaP, DU145 and PC3 were obtained from the Ameri-
can Type Culture Collection and maintained using the
suggested medium supplemented with 10% (v/v) fetal
calf serum (FCS), 3 mM L-glutamine, 100 μg/ml strepto-
mycin and 100 U/ml penicillin. LNCaP cells were grown
in RPMI 1640, and DU145 and PC3 cells were cultured in
DMEM. For the androgen-response experiments, LNCaP
cells were cultured for 24 hours in androgen-deprived
medium (RPMI 1640) with 5% (w/v) charcoal-stripped
fetal calf serum (FCS; Invitrogen, Carlsbad, CA, USA).
After 24 hours, cells were placed in fresh RPMI 1640
medium, with 10% (w/v) charcoal-treated FCS, and either
1 nM of the synthetic androgen R1881 (Perkin Elmer,
Wellesley, MA, USA) or equivalent volume of vehicle (eth-
anol) was added. Cells were harvested after 0, 6, 9, 12, 18,
24, and 48 hours for RNA isolation. Two independent cul-
tures of androgen-treated cells and of control cells (inde-
pendent biological replicates), were used for RNA
isolation.
In parallel, cells were harvested after 4 hours of hormone
treatment for isolation of DNA that was subsequently
used in ChIP assays, as described below. Total RNA was
purified from experimental and control cells by caesium
chloride cushion [49] after cell lysis (4 M guanidine iso-
thiocyanate; 0.1 M β-mercaptoethanol; 25 mM sodium
citrate pH 7.0). Total RNA (100 μg sample) was treated
with RNase-free DNase (RNeasy kit; Qiagen, Hilden, Ger-
many) for 15 min in the medium recommended by the
manufacturer to minimize genomic DNA contaminants,
and kept at -80°C until use.
Microarray experiments
The microarray platform used in this study was con-
structed using PCR-amplified cDNA fragments derived
from ORESTES clones [50], and spotted onto Type 7 STAR
glass slides (GE Healthcare, Piscataway, NJ, USA) as previ-
ously described [16]. This consists of a 9216-element
microarray (3355 unique cDNA probes spotted in dupli-
cate, plus positive and negative controls) enriched in
probes representing intronic (822 probes) and intergenic
(241 probes) ncRNAs. For each time point, 15 μg of
DNAse-treated total RNA from androgen-treated or
untreated control LNCaP cells were used to generate fluo-
rescent targets by incorporation of Cy5-dUTP in reverse
transcription reactions using the CyScribe First strand
cDNA labeling kit (GE Healthcare) and the protocol rec-
ommended by the manufacturer. Fluorescent targets
labeled with Cy3-dUTP were generated in parallel from a
reference RNA pool consisting of equimolar quantities ofBMC Biology 2007, 5:4 http://www.biomedcentral.com/1741-7007/5/4
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DNAse-treated total RNA from LNCaP, DU145 and PC3
cells.
For each independent biological replicate hybridization,
fluorescently labeled targets from each experimental time
point and the reference pool were combined and hybrid-
ized on an automated slide processor (GE Healthcare)
using protocols recommended by the manufacturer. For
each time point, two independent biological replicate
hybridizations were performed. Each hybridization used
one RNA, isolated from a different biological replicate of
androgen-treated or untreated control cells. Processed
slides were scanned in a microarray scanner (GenePix
4000 B; Molecular Devices, Sunnyvale, CA, USA). More
detailed information about microarray experiments and
analysis is provided as supplementary material (see Addi-
tional file 6) following MIAME guidelines [51].
Data acquisition and statistical analysis
Background-subtracted artifact-removed median intensi-
ties of both Cy3 and Cy5 emissions were extracted for
each spot from raw images using image analysis software
(ArrayVision version 8.0; GE Healthcare). Only spots with
signal intensity above the average plus 3 SD from a set of
negative controls (plant and bacterial DNA) were used in
subsequent analyses. As each microarray contains two
replicates of each spotted cDNA, a total of four replicate
measurements was obtained for each spot at each time
point. We evaluated the average coefficient of variation
between replicates of expression ratios between treated
and control cells calculated in two different ways. For each
time point, expression ratios between treated and control
cells were reconstructed either from (i) ratios relative to
the reference pool or (ii) Cy5 intensities obtained from
androgen-treated and control cells using a one-color
approach [52]. A smaller average coefficient of variation
between replicates was obtained with the latter approach,
and therefore we opted to use only the Cy5-labeled sam-
ple measurements to calculate the treatment:control sam-
ple ratios. We used the mean intensity signal (40%
trimmed) of each dataset for normalization between
experiments. Raw and normalized microarray intensities
were deposited in the Gene Expression Omnibus (GEO)
database [53] (accession number GSE5345).
Transcripts with statistically significant changes in expres-
sion in response to androgen stimulation were identified
using the statistical analysis of microarrays (SAM) method
[27]. Only transcripts showing significant expression
changes in at least three consecutive time points were
selected for further analysis, using as parameters the two-
class response (paired data), 1000 permutations, K-near-
est neighbors imputer, fold change ≥ 1.5 and FDR < 5%.
Expression profiles of SAM-selected transcripts were
grouped using hierarchical clustering (UPGMA with Eucli-
dean distance) and visualized using software (Spotfire
Decision Site; Spotfire, Somerville, MA, USA).
Orientation-specific RT-PCR and orientation-specific real-
time quantitative RT-PCR
Orientation-specific RT-PCR was performed as previously
described [16]. Briefly, 4 μg of DNase-treated total RNA
from androgen-treated or control LNCaP cells were used
to generate strand-specific cDNA. RNA samples were
selected from experimental time points that showed
higher fold change relative to control cells as identified in
microarray hybridizations. The same RNA samples were
used in microarray hybridizations and real-time PCR reac-
tions. To determine the levels of sense and antisense
intronic transcripts in androgen-treated and control cells,
we performed one orientation-specific reverse transcrip-
tion reaction for each strand using a single RNA sample,
and gene specific (forward or reverse) primers. RNA sam-
ples plus 0.9 μM of specific primer for either antisense or
sense strand of each intronic segment were heated to
75°C for 10 minutes to minimize artifacts derived from
the formation of secondary structure. Reverse transcrip-
tion was performed at 50°C for 60 min in a 50-μl volume,
using 200 U of reverse transcriptase (SuperscriptII; Invit-
rogen). Controls for the absence of self-priming were
obtained by performing reverse transcription in the
absence of primers, and controls for the absence of
genomic DNA contamination were obtained by incuba-
tion with primers in the absence of reverse transcriptase
enzyme. A reaction containing a primer complementary
to the coding region of TUBA6  (reverse primer: AGT-
GCCAGTGCGAACTTCATC) was carried out in parallel.
Reverse transcriptase was denatured for 30 min at 95°C.
One pair of internal primers for PCR amplification of
either the tubulin gene or the desired target intronic seg-
ment under study was added. For each intronic transcript,
cDNAs with sense or antisense orientation relative to the
corresponding gene were analyzed by three replicate
measurements in quantitative real-time PCR reactions.
For exonic transcripts, cDNA was obtained by reverse tran-
scription of RNA samples using oligo-dT primers, and the
levels of each message was also determined by three repli-
cate measurements in real-time PCR reactions with gene
specific primers. All real-time PCR reactions were carried
out in a volume of 20 μl for 40 cycles, according to the
manufacturer's instructions for the reagent (Sybr-Green
PCR core reagent; Applied Biosystems, Foster City, CA,
USA) using an automated sequence analyser (GenAmp
5700; Applied Biosystems). For quantitative results, the
levels of each transcript detected by real-time quantitative
PCR was normalized to the level of tubulin, and repre-
sented as fold change using the ΔCt method [54]. Quanti-
tative results for a transcript in androgen-treated cells were
expressed as relative fold change with respect to the valueBMC Biology 2007, 5:4 http://www.biomedcentral.com/1741-7007/5/4
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of the target transcript in the control (ethanol vehicle),
which was set at unity.
Rapid amplification of cDNA ends-PCR and northern blot
For RACE-PCR we used a commercial cDNA library pre-
pared from poly(A)+ RNA isolated from a human pros-
tatic adenocarcinoma cell line (Human XG marathon-
ready cDNA, catalog no. 7498-1; BD Biosciences, Palo
Alto, CA, USA). Two rounds of PCR reactions were per-
formed for each intronic transcript using two pairs of
gene-specific primers in nested PCR reactions. To obtain a
long (~5 kb) transcript corresponding to asGAS6, a gene-
specific PCR was performed using a forward primer com-
plementary to the partial asGAS6 cDNA sequence depos-
ited in the microarray and a reverse primer
complementary to the antisense transcript deposited in
[GenBank: AK123478]. The PCR product was sequenced
to confirm the identity. To confirm the size and orienta-
tion of the full-length asGAS6 obtained by PCR, a north-
ern blot was performed using a commercial membrane
containing 2 μg poly(A)+ RNA from 10 human tissues
(First Choice Human Blot 4; Ambion, Austin, TX, USA),
using a probe complementary to the antisense strand of
GAS6  intronic transcript spotted onto the microarray.
Sense α-[32P]-CTP-labeled RNA probes were obtained by
in vitro transcription using T7 RNA polymerase (Ribo-
probe; Promega, Madison, WI, USA). Hybridization and
wash procedures were carried out as described in the
human blot manufacturer's protocol (Ambion). The
probed blot was processed in a phosphorimager (Storm;
GE Healthcare).
Putative identification of androgen-responsive elements 
and chromatin immunoprecipitation assay
Using a bioinformatics approach, we searched for regions
with similarity to the palindromic ARE consensus AGAA-
CAnnnTGTTCT [40], obtained from the TRANSFAC data-
base of eukaryotic cis-acting regulatory DNA elements
[55]. The search was conducted within a 3-kb region of
genomic sequence, upstream of the putative transcrip-
tional start sites of the 39 androgen-regulated intronic
transcripts identified in the microarray analysis. When
available, RACE-extended fragments were used. ChIP
assays were performed as described in the literature [56-
58], and specific PCR primers were designed to detect
binding of the androgen receptor to the putative ARE pro-
moter sequence of asMYO5A, identified by in silico analy-
sis. A chromatin immunoprecipitation assay kit (catalog
no. 17–295, Millipore, Billerica, MA, USA) was used, with
the protocols recommended by the manufacturer. Briefly,
LNCaP cells treated with androgen or vehicle as described
above were fixed with 1% formaldehyde for 10 min at
room temperature and lysed with sodium dodecyl sulfate
lysis buffer. Cell lysates were sonicated to shear the DNA
between 200 and 1000 bp using a sonic dismembrator
(Model 500; Fischer Scientific, Waltham, MA, USA). Aliq-
uots of the lysate (100 μL). containing approximately 2 ×
106 cells were diluted in 900 μL dilution buffer, and 10 μL
from each aliquot (1% of total lysate) were separated and
used subsequently as loading controls for input DNA. Par-
allel chromatin immunoprecipitation reactions were per-
formed with either 3 μg polyclonal antibody anti-AR (H-
280; Santa Cruz Technologies, Santa Cruz, CA, USA) or 1
μg normal mouse IgG (negative control). Immunoprecip-
itated chromatin fractions and respective loading control
fractions were treated for cross-link reversal, treated with
RNase A and proteinase K, and DNA fragments were puri-
fied using Spin Columns. An aliquote (2 μl) from each
eluted DNA was used as template in PCR reactions with
the following primers flanking the putative asMYO5A
ARE: forward, TTTGCTGGATAAGGATTCCCA; reverse,
AGTTCCTTAAACTTTAGCTTAGAAAAAGGA. Similar reac-
tions were performed with control primers designed to
the known AREIII motif of the PSA (prostate-specific anti-
gen) enhancer (positive control) (forward primer: GCT-
CAGCCTTTGTCTCTGATGA, reverse:
TGCAAGATGATATCTCTCTCAGATCC) and to the TUBA6
non-related upstream genomic sequence (negative con-
trol) (forward primer: GACTACAGGTGTGCGCCATCAT,
reverse: TGCCGTGTTCCAGGCAGTAG). For each DNA
target, semi-quantitative PCR was performed by running
parallel reactions with increasing numbers of PCR cycles
(25, 30 or 40 cycles). Cycle runs of 25 and 30 PCR cycles
resulted in non-saturated amplification of each DNA tar-
get in immunoprecipitated and input DNA fractions from
androgen-treated or control cells (data not shown). Equal
volumes from each PCR reaction were loaded and sepa-
rated in a 3% agarose gel. The intensity of PCR-amplified
bands was determined by gel densitometry (Image Mas-
ter; GE Healthcare).
Accession numbers
We have deposited in GenBank the following sequence
data under the indicated accession numbers (in parenthe-
ses): antisense intronic ITGA6  [GenBank: DQ866759],
antisense intronic DNAJC3 [GenBank: DQ866760], anti-
sense intronic MYO5A [GenBank: DQ866761], intronic
STARD13  [GenBank: DQ866762], antisense intronic
GAS6 [GenBank: DQ866763], antisense intronic RAB25
[GenBank: DQ866751], antisense intronic ADD3 [Gen-
Bank: DQ866752], intronic ACTN4  [GenBank:
DQ866753], intronic SAP18  [GenBank: DQ866754],
intronic ERG [GenBank: DQ866755], intronic KDELR2
[GenBank: DQ866756], intronic FLJ10154 [GenBank:
DQ866757], and intronic ATF2 [GenBank: DQ866758].
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